Replies to post #368839 on Amarin Corp Plc (AMRN)

[Whalatane]

Not sure price reduction is the solution ?
Until you can win the infringement case it is
There’s a price demand flexibility curve here …. From what I remember from Econ … correct if U like
Price affects demand
Higher volume of sales can offset the less profit per sale

They can operate AMRN out of a warehouse in an “ economic incentive “ zone or what ever it’s called now … with most of staff working from home

My oldest son runs a $25-$30,000 a day marketing program from his apt / condo
Last time he was in HQ … about half an hr away … was mid Dec 2021

Kiwi

[studythosestocks]

Excellent points and I agree wholeheartedly if the entire amount of Vascepa scripts are currently being filled. Let me share a very simplistic (not flawless) example of why I think this could be the start of growing scripts. Here it goes.

Just for fun lets say that right now there are 130,000 scripts weekly written for V cardiovascular indication. Let’s say the generics are producing 30,000 bottles weekly. The other 100,000 should be filled with brand V(actually all of them but we know obvious infringment occurring).
However they are not since so many pharmacies are auto substituting V for the generic V. The patient either gets an email if electronically done or if in person from the pharmacists telling them that their script cannot be filled at this time because they are out of V (which for the pharmacist really means gV) and to check back next week. After the client checks back next week, they still do not have their shipment of gV in. The patient gets frustrated and ends up not filling his/her prescription at all. This has been discussed several times by both JT and KM in different presentations. They have said that it is the "new" script that is so important because it comes with refills with time. If a new script never fills then no refills will be filled either. If a refill then possibly no other refills filled. If it is filled in 2 weeks when the new shipment comes in with gV then it will be gV from then on. Let’s say this is happening in 10% of these new or refill scripts weekly for brand Vascepa. This would be 10,000 scripts (figured from the 100,000 left over after the 30,000 gV infringing prescriptions have been filled). I know this is very simplistic but if CVS was the only pharmacy in the US (which it isn't but strictly for simplicity), then now an extra 10,000 scripts will be filled which would not have been filled before (since the 30K infringed scripts was the entire gV available and they were used up already and the 10,000 delayed would have eventually either not been filled or filled with gV later).

Also, we have heard many times that when patients go to refill their V they are being autorefilled with gV. Now this will stop at the CVS Caremarks. This may mean however as you pointed out that the gV will be used elsewhere IF there was gV to even be used elsewhere since it appears to consistently be a supply issue.

Finally, it helps in marketing. For those who take things daily, they look at the bottle and look at the tablet or capsule and over time they recognize what is "normal" to them. If they see the words Vascepa and see the clear Vascepa gel caps daily, they will notice over time when they are autoswitched to the yellow gV capsules hopefully and notice the texture, burps, etc associated with the generic and recognize something isn't right. If they have never had the Brand V they would never know the difference.

These are just some of my thoughts and realize not perfect thoughts

[Bolio98]

Why are you assuming there was any price reduction? Did AMRN announce it? Maybe CVS is just noticing that with the coupon being applied AMRN is much cheaper at it's current price and they see the volume of coupon sales they are putting through.